Compugen Ltd. Announces Proposed Public Offering of Ordinary Shares
February 27 2014 - 4:09PM
Business Wire
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) today
announced that it has commenced an underwritten public offering of
its ordinary shares. All of the ordinary shares in the offering are
being offered by Compugen. The offering is subject to market and
other conditions, and there can be no assurance as to whether or
when the offering may be completed, or as to the actual size or
terms of the offering.
Jefferies LLC is acting as the sole bookrunner for the proposed
offering. JMP Securities LLC, Oppenheimer & Co. Inc. and
Chardan Capital Markets are acting as co-managers.
A shelf registration statement on Form F-3 relating to the
public offering of the ordinary shares described above has been
filed with the Securities and Exchange Commission (the “SEC”) and
is effective. A preliminary prospectus supplement relating to the
offering will be filed with the SEC and will be available on the
SEC’s website at http://www.sec.gov. Copies of the preliminary
prospectus supplement and the accompanying prospectus relating to
this offering may also be obtained, when available, from Jefferies
LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 12th Floor, New York, NY, 10022, by telephone at
877-547-6340, or by email at
Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Compugen
Compugen is a leading drug discovery company focused on
therapeutic proteins and monoclonal antibodies to address important
unmet needs in the fields of immunology and oncology. The Company
utilizes a broad and continuously growing integrated infrastructure
of proprietary scientific understandings and predictive platforms,
algorithms, machine learning systems and other computational
biology capabilities for the in silico (by computer) prediction and
selection of product candidates, which are then advanced in its
Pipeline Program. The Company's business model includes
collaborations covering the further development and
commercialization of product candidates at various stages from its
Pipeline Program and various forms of research and discovery
agreements, in both cases providing Compugen with potential
milestone payments and royalties on product sales or other forms of
revenue sharing. In 2012, Compugen established operations in
California for the development of oncology and immunology
monoclonal antibody therapeutic candidates against Compugen drug
targets.
Forward-looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to our expectations
regarding the completion of the proposed public offering. Actual
results or developments may differ materially from those projected
or implied in these forward looking statements. Factors that may
cause such a difference include, without limitation, risks and
uncertainties related to the final terms of the proposed offering,
market and other conditions, the satisfaction of customary closing
conditions related to the proposed offering and the impact of
general economic, industry or political conditions in the United
States or internationally. There can be no assurance that we will
be able to complete the proposed offering. You should not place
undue reliance on these forward looking statements, which apply
only as of the date of this press release. Additional risks and
uncertainties relating to the proposed offering and our business
can be found under the heading "Risk Factors" in the filings that
we periodically make with the SEC and in the preliminary prospectus
supplement related to the proposed offering to be filed with the
SEC on the date hereof. In addition, the forward-looking statements
included in this press release represent our views as of the date
of this press release. We anticipate that subsequent events and
developments will cause our views to change. However, while we may
elect to update these forward-looking statements at some point in
the future, we specifically disclaim any obligation to do so. These
forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
Compugen Ltd.Tsipi HaitovskyGlobal Media
Liaison+972-52-598-9892tsipih@netvision.net.il
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024